查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1932181

RNA合成市場依產品類型、技術、應用、規模和最終用戶分類，全球預測（2026-2032年）

RNA Synthesis Market by Product Type, Technology, Application, Scale, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計 RNA 合成市場在 2025 年的價值為 48.8 億美元，在 2026 年成長至 57.9 億美元，到 2032 年達到 184.5 億美元，複合年成長率為 20.91%。

關鍵市場統計數據
基準年 2025 48.8億美元
預計年份：2026年 57.9億美元
預測年份 2032 184.5億美元
複合年成長率 (%) 20.91%

本書權威概述了RNA合成在現代治療方法、診斷和轉化研究中的核心驅動力及其實際應用價值。

RNA合成技術已從一門學術專長發展成為現代生命科學創新的核心支柱，為疫苗、治療藥物、診斷方法和基礎研究奠定了基礎。化學和酵素學的進步降低了技術門檻，拓展了合成RNA的範圍，使其從短寡核苷酸延伸至長鏈、高度修飾的傳訊RNA構建體。同時，自動化、純化和分析能力的提升顯著提高了合成通量和可重複性，催生了新的應用，並加速了概念轉化為臨床。

技術創新與產業結構調整的整合將如何重塑RNA合成能力、商業化與供應鏈韌性

RNA合成領域正經歷一系列變革，其意義遠不止於產量和純度的逐步提升。曾經的小眾酵素法如今已發展成為可擴展的平台，直接挑戰傳統的化學方法，尤其是在建構長鏈RNA和需要特異性修飾的序列方面。同時，化學合成對於短寡核苷酸以及需要高度控制鹼基修飾的應用仍然至關重要，而溶液相和固相亞磷醯胺法在自動化和綠色化學領域也在不斷發展。

了解近期關稅調整如何推動整個價值鏈的供應鏈區域化、來源多元化和策略性製造選擇。

近期貿易政策的變化和關稅調整對RNA合成價值鏈產生了多方面的影響，波及採購、生產經濟和戰略規劃等各個環節。對特種試劑、關鍵原料和精密設備的關稅上漲增加了進口投入品的到岸成本，並可能改變供應商的選擇標準。為此，製造商和研發人員正在重新評估其供應商關係和庫存策略，以維持生產效率並按時完成計劃里程碑。

可操作的細分訊息，揭示產品類型、合成技術、應用、規模和最終用戶如何塑造不同的商業性和技術路徑。

細分市場洞察凸顯了不同產品類型、技術、應用、規模和最終用戶如何產生不同的需求和商業性路徑。產品層面的差異體現在傳訊RNA）和小型調控寡核苷酸（如微型RNA、siRNA和單嚮導RNA）之間。信使RNA通常需要較長的定序時間和複雜的純化過程，而小型調控寡核苷酸則更注重精確性、修飾化學和可擴展的合成。轉移RNA和其他特殊構建體需要客製化的修飾和折疊策略，這會影響合成路徑和分析負擔。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和戰略要務將影響選址、夥伴關係和供應鏈結構。

區域趨勢正在深刻影響美洲、歐洲、中東和非洲以及亞太地區RNA合成領域的競爭格局和業務運作。美洲地區擁有強大的生物製藥研發生態系統，以及密集的合約供應商和試劑供應商網路，為快速原型製作和轉化應用提供了有力支持。該地區的監管互動和投資者活動持續推動對平台技術和商業化生產能力的關注。

供應商、合約研發生產機構 (CDMO) 和開發商之間的策略行動和競爭發展推動了 RNA 合成領域的產能擴張、夥伴關係和差異化。

產業相關人員正積極推行多項策略性舉措，以期在整個RNA合成過程中創造價值。主要試劑和儀器供應商正投資於平台升級和自動化，以應對高通量和高重複性的挑戰。同時，合約研發生產機構（CDMO）正在擴大產能，為客戶提供從原型到臨床應用的一站式整合服務。生物技術和製藥公司也擴大與利基技術供應商合作，以獲得獨特的化學方法、酵素平台和製程改進方法，從而在速度和生產成本方面實現差異化。

產業領導者在建立穩健、敏捷且擴充性的RNA合成能力的同時，應對監管和供應風險，需要滿足切實可行的營運和策略要求。

產業領導者應優先考慮一套精簡的策略行動方案，以便在保持多種選擇的同時快速執行。首先，實現關鍵試劑和設備的採購多元化，並對二級供應商進行資格認證，以降低單一來源風險，並在出現供應中斷時加快回應速度。其次，當序列長度或修飾模式適合酵素合成時，應有選擇地投資酵素合成平台，同時維持化學合成能力，以滿足短寡核苷酸的需求和特殊化學反應。

我們採用透明、以證據為導向的研究途徑，結合專家訪談、文獻和專利研究、供應鏈映射和情境檢驗，為策略決策提供支援。

本分析整合了多種資訊來源，全面且檢驗展現了RNA合成領域的發展趨勢。主要研究包括對相關領域專家進行保密訪談，這些專家包括試劑供應商、契約製造、生物技術創新者和監管專家，旨在深入了解他們的業務重點和決策標準。此外，我們也廣泛查閱了同行評審文獻、專利申請、技術白皮書和已發布的監管指南，以交叉檢驗技術趨勢和品管要求。

從技術、營運和政策層面進行策略整合，以確定將RNA合成技術進一步轉化為可靠產品和可擴展營運的優先事項。

累積評估結果顯示，RNA合成產業正處於積極變革時期期，其驅動力包括技術成熟、監管要求不斷變化以及供應鏈優先事項的轉變。目前，RNA合成技術呈現頻譜權衡取捨，這些取捨將序列和修飾的複雜性與平台選擇聯繫起來：酶法在合成較長的RNA結構方面越來越受歡迎，而化學合成在合成較短的寡核苷酸和客製化化學方法方面仍然佔據主導地位。這些技術決策與規模、品質系統和地理擴張的營運決策密不可分。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：RNA合成市場（依產品類型分類）

  • 傳訊RNA
  • 微型RNA
  • 單嚮導RNA
  • 小干擾RNA
  • 轉移RNA

第9章 RNA合成市場：依技術分類

  • 化學合成
    • 液相
    • 固相亞磷醯胺法
  • 酵素合成
    • 體外轉錄
    • 滾動圓圈轉移

第10章 RNA合成市場：依應用領域分類

  • 診斷
    • 臨床診斷
    • 照護現場診斷
  • 調查
    • 基礎研究
    • 藥物發現
  • 治療藥物
    • 遺傳性疾病
    • 感染疾病
    • 腫瘤學
  • 疫苗
    • 快速反應疫苗
    • 季節性疫苗

第11章 依生產規模分類的RNA合成市場

  • 商業規模
    • 大量生產
    • GMP生產
  • 實驗室規模
    • 原型階段
    • 研究與開發應用

第12章 依最終用戶分類的RNA合成市場

  • 學術機構
  • 生技公司
  • CRO（受託研究機構）
  • 製藥公司

第13章 RNA合成市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 RNA合成市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國RNA合成市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 美國RNA合成市場

第17章 中國RNA合成市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Aldevron, LLC
  • Alnylam Pharmaceuticals, Inc.
  • Ansa Biotechnologies, Inc.
  • ATDBio Ltd.
  • Azenta Life Sciences, Inc.
  • BioNTech SE
  • ChemGenes Corporation
  • CureVac NV
  • EnPlusOne Biosciences, Inc.
  • Eurofins Genomics Germany GmbH
  • GenScript Biotech Corporation
  • Integrated DNA Technologies, Inc.
  • Kilobaser, Inc.
  • Merck KGaA
  • Moderna, Inc.
  • New England Biolabs, Inc.
  • Sarepta Therapeutics, Inc.
  • Thermo Fisher Scientific Inc.
  • Twist Bioscience Corporation
  • WAVE Life Sciences Ltd.
Product Code: MRR-7B550E008FCF

The RNA Synthesis Market was valued at USD 4.88 billion in 2025 and is projected to grow to USD 5.79 billion in 2026, with a CAGR of 20.91%, reaching USD 18.45 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.88 billion
Estimated Year [2026] USD 5.79 billion
Forecast Year [2032] USD 18.45 billion
CAGR (%) 20.91%

An authoritative overview framing RNA synthesis as a central enabler of modern therapeutics, diagnostics, and translational research with practical implications

RNA synthesis has moved from an academic specialty to a central pillar of contemporary life sciences innovation, underpinning vaccines, therapeutics, diagnostics, and basic research. Advances in chemistries and enzymology have lowered technical barriers and broadened the range of deliverables from short oligonucleotides to long, modification-rich messenger RNA constructs. Parallel improvements in automation, purification, and analytical capabilities have transformed throughput and reproducibility, enabling new applications and enabling faster translation from concept to clinic.

Stakeholders across the value chain-reagent suppliers, contract development and manufacturing organizations, academic laboratories, and biopharma companies-are reconfiguring priorities to capture the promise of RNA-based modalities. Regulatory pathways are evolving in response to accelerated vaccine programs and novel therapeutic approaches, prompting closer dialogue between developers and agencies. Investors and strategic partners are increasingly focused on platform technologies that can flex between research-scale needs and commercial-scale production.

As the ecosystem converges around reproducible, scalable synthesis routes and resilient supply chains, organizations that align technology choices with application needs and regulatory expectations will be best positioned to move from promising data to commercial impact. This report provides a structured perspective on those alignments and their operational implications.

How converging technological advances and structural industry realignments are reshaping RNA synthesis capabilities, commercialization, and supply chain resilience

The landscape of RNA synthesis is undergoing a set of transformational shifts that extend beyond incremental improvements in yield or purity. Enzymatic methods that once were niche are now maturing into scalable platforms that directly challenge traditional chemical approaches, particularly for longer constructs and sequences requiring site-specific modifications. At the same time, chemical synthesis remains indispensable for short oligonucleotides and applications that demand high control over base modifications, with liquid phase and solid phase phosphoramidite approaches continuing to evolve in automation and green chemistry.

These technical shifts are paralleled by structural changes across the ecosystem. Contract development and manufacturing providers are expanding capabilities to offer end-to-end services, integrating synthesis, formulation, and analytics to meet customer expectations for speed and quality. Diagnostics developers and vaccine manufacturers are demanding rapid-turnaround production and adaptable manufacturing lines that can toggle between research-scale prototyping and GMP-grade output. Regulatory frameworks and quality systems are being updated to reflect modality-specific risks and control strategies, increasing the premium on robust process characterization.

Supply chain resilience has risen to the top of strategic agendas, driving diversification of suppliers and geographic footprint decisions. Partnerships and platform licensing are becoming strategic levers to accelerate market entry while managing capital intensity. Collectively, these changes are reshaping how organizations prioritize investments in technology, talent, and infrastructure.

Understanding how recent tariff adjustments are catalyzing supply chain regionalization, supplier diversification, and strategic manufacturing choices across the value chain

Recent trade policy shifts and tariff adjustments have exerted a multifaceted influence on the RNA synthesis value chain, producing effects that ripple through sourcing, manufacturing economics, and strategic planning. Tariffs on specialized reagents, critical raw materials, and precision instrumentation increase the landed cost of imported inputs and can alter supplier selection criteria. In response, manufacturers and developers are reassessing supplier relationships and inventory strategies to maintain throughput and meet time-sensitive project milestones.

The policy environment has accelerated interest in nearshoring and regionalization of critical manufacturing functions. Firms weighing relocation or expansion of production facilities cite supply continuity, shorter lead times, and reduced exposure to cross-border disruptions as core motivations. These location decisions intersect with regulatory requirements and workforce availability, prompting a holistic view of site selection that balances cost pressures with operational reliability.

Tariff-driven cost impacts also influence the economics of platform choice. Organizations may favor synthesis routes and process intensifications that reduce raw material intensity or shift demand toward locally available reagents. Meanwhile, downstream stakeholders such as contract manufacturers and diagnostic suppliers are expanding supplier networks and building contingency stocks to preserve production cadence. The collective effect is an accelerated shift toward resilient sourcing strategies, strategic inventory management, and localized capability development to mitigate the cumulative effects of tariff changes.

Actionable segmentation intelligence revealing how product types, synthesis technologies, applications, scale, and end users shape distinct commercial and technical pathways

Insights derived from segmentation clarify how different product types, technologies, applications, scales, and end users create distinct needs and commercial pathways. Product-level distinctions separate messenger RNA, which typically demands long-sequence capabilities and complex purification, from small regulatory oligonucleotides such as microRNA, small interfering RNA, and single guide RNA that prioritize precision, modification chemistry, and scalable synthesis. Transfer RNA and other specialized constructs require tailored modification and folding strategies that influence both synthesis route and analytical burden.

Technological segmentation highlights a bifurcation between chemical synthesis modalities and enzymatic approaches. Chemical synthesis, encompassing liquid phase workflows and solid-phase phosphoramidite techniques, remains the workhorse for short oligos and applications requiring fine-grained chemical modifications. Enzymatic synthesis, including in vitro transcription and rolling circle transcription methods, is gaining traction for producing longer transcripts and for workflows that benefit from reduced reagent complexity and simpler scale-up. The relative merits of each approach depend on sequence length, modification requirements, cost-to-quality considerations, and downstream application.

Application-focused segmentation frames diagnostics, research, therapeutics, and vaccines as distinct demand centers. Diagnostics divide into clinical diagnostics and point-of-care formats, each with unique regulatory and supply chain pressures. Research needs bifurcate into basic research and drug discovery, where throughput and proof-of-concept timelines differ. Therapeutic applications span genetic disorders, infectious diseases, and oncology, each influencing tolerability, dosing, and manufacturing rigor. Vaccines, differentiated into rapid response and seasonal formats, place different priorities on speed, scalability, and batch-to-batch consistency.

Scale considerations differentiate commercial-scale operations, which include bulk manufacturing and GMP production, from laboratory-scale activities focused on prototyping and R&D. These scale distinctions drive choices in capital equipment, process control, and quality systems. Finally, end-user segmentation-academic institutions, biotechnology companies, contract research and manufacturing organizations, and pharmaceutical companies-determines purchasing patterns, customization needs, and tolerance for risk in adopting emerging technologies. Taken together, these segmentation lenses inform targeted product and service strategies aligned with distinct technical and market realities.

Regional dynamics and strategic imperatives across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence site selection, partnerships, and supply chain architecture

Regional dynamics shape the competitive and operational contours of RNA synthesis in meaningful ways across the Americas, Europe, Middle East & Africa, and Asia-Pacific. The Americas combine robust biopharma R&D ecosystems with a dense network of contract providers and reagent suppliers, which supports rapid prototyping and translational pathways. Regulatory engagement and investor activity in the region continue to drive emphasis on platform technologies and commercial-scale production capabilities.

Europe, Middle East & Africa feature strong academic-industrial collaboration and advanced manufacturing expertise, with regulatory systems that emphasize rigorous quality frameworks. The region benefits from a deep pool of specialized service providers and analytical capability, often focusing on high-complexity therapeutic programs and tailored manufacturing solutions. Cross-border collaboration and harmonization efforts influence where companies choose to site specialized production and analytical capacity.

Asia-Pacific has emerged as a pivotal hub for both high-volume manufacturing and innovative startups. Investments in process automation, additive capacity, and workforce development have supported growing capabilities in both chemical and enzymatic synthesis. Regional supply chains often provide competitive cost structures and scaling efficiency, while local regulatory frameworks are evolving to accommodate novel modalities. Taken together, these regional profiles guide strategic choices in site selection, partnership formation, and supply chain architecture for organizations seeking global operational resilience.

Strategic behaviors and competitive plays among suppliers, CDMOs, and developers that drive capability expansion, partnerships, and differentiation in RNA synthesis

Industry participants are pursuing multiple strategic plays to capture value along the RNA synthesis continuum. Leading reagents and equipment suppliers are investing in platform enhancements and automation to address throughput and reproducibility challenges, while contract development and manufacturing organizations expand capacity to provide integrated end-to-end services for customers migrating from prototype to clinical material. Biotech and pharmaceutical companies are increasingly partnering with niche technology providers to secure proprietary chemistries, enzymatic platforms, or process intensification methods that offer differentiation in speed or cost of goods.

Strategic alliances and licensing agreements are common mechanisms for accelerating access to complementary capabilities, particularly where timeline pressures favor collaboration over in-house development. Investment in analytical capability and quality systems is a recurrent theme, reflecting the regulatory emphasis on robust characterization and control strategies for RNA products. Companies are also differentiating through service offerings that combine synthesis with formulation, stability testing, and regulatory support to reduce handoffs and shorten development timelines.

Talent and IP positioning remain critical. Organizations that acquire or cultivate cross-disciplinary expertise-combining molecular biology, process engineering, and regulatory science-are better equipped to design scalable processes and navigate approval pathways. Finally, sustainability and supply continuity measures are emerging considerations as companies seek to de-risk operations and meet stakeholder expectations around responsible sourcing and environmental management.

Practical operational and strategic imperatives for industry leaders to build resilient, agile, and scalable RNA synthesis capabilities while managing regulatory and supply risks

Industry leaders should prioritize a compact set of strategic actions that preserve optionality while enabling execution at speed. First, diversify sourcing and qualify secondary suppliers for critical reagents and instrumentation to reduce single-source risk and shorten response times when disruptions occur. Second, invest selectively in enzymatic synthesis platforms where sequence length or modification patterns favor this route, while retaining chemical synthesis capacity for short oligonucleotide needs and specialized chemistries.

Third, design manufacturing footprints for flexibility by adopting modular production units and digital control systems that allow rapid switching between laboratory-scale prototyping and GMP-compliant commercial runs. Fourth, strengthen partnerships with contract developers and analytical specialists to accelerate process validation and regulatory submissions while avoiding unnecessary capital intensity. Fifth, engage early and frequently with regulatory authorities to align on control strategies for novel modalities and to anticipate data requirements that accompany different application classes.

Sixth, build workforce capabilities through targeted hiring and cross-training programs that bridge molecular biology, process engineering, and quality assurance. Seventh, embed sustainability considerations into procurement and process design to reduce waste and improve resource efficiency. Finally, maintain a disciplined approach to IP strategy that balances open innovation with protection of proprietary process elements that confer competitive advantage. These actions together create a resilient, agile operating model capable of translating scientific advances into commercial outcomes.

A transparent, evidence-driven research approach combining primary expert interviews, literature and patent review, supply chain mapping, and scenario validation to inform strategic decisions

The analysis synthesized multiple information streams to produce a comprehensive and verifiable perspective on RNA synthesis dynamics. Primary research included confidential interviews with subject matter experts across reagent suppliers, contract manufacturers, biotech innovators, and regulatory specialists, providing grounded insights into operational priorities and decision criteria. Complementing primary inputs, an extensive review of peer-reviewed literature, patent filings, technical white papers, and publicly disclosed regulatory guidance allowed cross-validation of technology trends and quality control expectations.

Supply chain mapping and vendor landscape analysis utilized procurement disclosures, public company reports, and trade data to identify concentration risks and common mitigation strategies. Technology performance comparisons drew on method-specific performance metrics reported in the literature and validated through expert consultation. Scenario analysis was used to assess the expected operational impacts of policy changes and tariff adjustments, focusing on strategic implications rather than quantitative market projections.

Data integrity was ensured through triangulation across independent sources and iterative validation with interviewees. Segmentation logic was developed to reflect real-world purchasing and development flows, mapping product types, technologies, applications, scale, and end-user needs to distinct operational strategies. The result is an evidence-based synthesis designed to inform strategic planning, technology selection, and supply chain decisions.

A strategic synthesis of technical, operational, and policy factors that clarifies priorities for translating advances in RNA synthesis into reliable products and scalable operations

The cumulative assessment highlights a sector in active transition-driven by technological maturation, evolving regulatory expectations, and shifting supply chain priorities. RNA synthesis technologies now present a spectrum of trade-offs that link sequence and modification complexity to platform choice, with enzymatic methods attracting attention for long-form constructs while chemical synthesis retains primacy for short oligonucleotides and bespoke chemistries. These technical decisions are inseparable from operational decisions about scale, quality systems, and geographic footprint.

Policy developments and tariff shifts are accelerating strategic moves toward regionalization and supplier diversification, but organizations that combine localization with partnerships and strong analytical capabilities will preserve both cost competitiveness and manufacturing resilience. Across regions, differing strengths in R&D, manufacturing, and regulatory frameworks create opportunities for cross-border partnerships and role specialization. Companies that align technology investments with application-specific needs, engage early with regulators, and adopt flexible manufacturing paradigms will be best positioned to convert scientific promise into reliable products and services.

The path forward requires coordinated attention to technology selection, supply chain design, workforce development, and regulatory strategy. The insights in this report are intended to help leaders prioritize investments and operational changes that reduce risk, accelerate time to critical milestones, and unlock the full potential of RNA-based modalities.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. RNA Synthesis Market, by Product Type

  • 8.1. Messenger Rna
  • 8.2. Micro Rna
  • 8.3. Single Guide Rna
  • 8.4. Small Interfering Rna
  • 8.5. Transfer Rna

9. RNA Synthesis Market, by Technology

  • 9.1. Chemical Synthesis
    • 9.1.1. Liquid Phase
    • 9.1.2. Solid Phase Phosphoramidite
  • 9.2. Enzymatic Synthesis
    • 9.2.1. In Vitro Transcription
    • 9.2.2. Rolling Circle Transcription

10. RNA Synthesis Market, by Application

  • 10.1. Diagnostics
    • 10.1.1. Clinical Diagnostics
    • 10.1.2. Point Of Care Diagnostics
  • 10.2. Research
    • 10.2.1. Basic Research
    • 10.2.2. Drug Discovery
  • 10.3. Therapeutics
    • 10.3.1. Genetic Disorders
    • 10.3.2. Infectious Diseases
    • 10.3.3. Oncology
  • 10.4. Vaccines
    • 10.4.1. Rapid Response Vaccines
    • 10.4.2. Seasonal Vaccines

11. RNA Synthesis Market, by Scale

  • 11.1. Commercial Scale
    • 11.1.1. Bulk Manufacturing
    • 11.1.2. Gmp Production
  • 11.2. Laboratory Scale
    • 11.2.1. Prototyping
    • 11.2.2. Rd Use

12. RNA Synthesis Market, by End User

  • 12.1. Academic Institutions
  • 12.2. Biotechnology Companies
  • 12.3. Contract Research Organizations
  • 12.4. Pharmaceutical Companies

13. RNA Synthesis Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. RNA Synthesis Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. RNA Synthesis Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States RNA Synthesis Market

17. China RNA Synthesis Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Aldevron, LLC
  • 18.6. Alnylam Pharmaceuticals, Inc.
  • 18.7. Ansa Biotechnologies, Inc.
  • 18.8. ATDBio Ltd.
  • 18.9. Azenta Life Sciences, Inc.
  • 18.10. BioNTech SE
  • 18.11. ChemGenes Corporation
  • 18.12. CureVac N.V.
  • 18.13. EnPlusOne Biosciences, Inc.
  • 18.14. Eurofins Genomics Germany GmbH
  • 18.15. GenScript Biotech Corporation
  • 18.16. Integrated DNA Technologies, Inc.
  • 18.17. Kilobaser, Inc.
  • 18.18. Merck KGaA
  • 18.19. Moderna, Inc.
  • 18.20. New England Biolabs, Inc.
  • 18.21. Sarepta Therapeutics, Inc.
  • 18.22. Thermo Fisher Scientific Inc.
  • 18.23. Twist Bioscience Corporation
  • 18.24. WAVE Life Sciences Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL RNA SYNTHESIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RNA SYNTHESIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL RNA SYNTHESIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL RNA SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL RNA SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RNA SYNTHESIS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL RNA SYNTHESIS MARKET SIZE, BY SCALE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RNA SYNTHESIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL RNA SYNTHESIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RNA SYNTHESIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL RNA SYNTHESIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES RNA SYNTHESIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA RNA SYNTHESIS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RNA SYNTHESIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RNA SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL RNA SYNTHESIS MARKET SIZE, BY MESSENGER RNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL RNA SYNTHESIS MARKET SIZE, BY MESSENGER RNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL RNA SYNTHESIS MARKET SIZE, BY MESSENGER RNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RNA SYNTHESIS MARKET SIZE, BY MICRO RNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL RNA SYNTHESIS MARKET SIZE, BY MICRO RNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL RNA SYNTHESIS MARKET SIZE, BY MICRO RNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RNA SYNTHESIS MARKET SIZE, BY SINGLE GUIDE RNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RNA SYNTHESIS MARKET SIZE, BY SINGLE GUIDE RNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RNA SYNTHESIS MARKET SIZE, BY SINGLE GUIDE RNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RNA SYNTHESIS MARKET SIZE, BY SMALL INTERFERING RNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RNA SYNTHESIS MARKET SIZE, BY SMALL INTERFERING RNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RNA SYNTHESIS MARKET SIZE, BY SMALL INTERFERING RNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RNA SYNTHESIS MARKET SIZE, BY TRANSFER RNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RNA SYNTHESIS MARKET SIZE, BY TRANSFER RNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RNA SYNTHESIS MARKET SIZE, BY TRANSFER RNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL RNA SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RNA SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RNA SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RNA SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RNA SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RNA SYNTHESIS MARKET SIZE, BY LIQUID PHASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RNA SYNTHESIS MARKET SIZE, BY LIQUID PHASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RNA SYNTHESIS MARKET SIZE, BY LIQUID PHASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RNA SYNTHESIS MARKET SIZE, BY SOLID PHASE PHOSPHORAMIDITE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RNA SYNTHESIS MARKET SIZE, BY SOLID PHASE PHOSPHORAMIDITE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RNA SYNTHESIS MARKET SIZE, BY SOLID PHASE PHOSPHORAMIDITE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RNA SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RNA SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RNA SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RNA SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RNA SYNTHESIS MARKET SIZE, BY IN VITRO TRANSCRIPTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RNA SYNTHESIS MARKET SIZE, BY IN VITRO TRANSCRIPTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RNA SYNTHESIS MARKET SIZE, BY IN VITRO TRANSCRIPTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RNA SYNTHESIS MARKET SIZE, BY ROLLING CIRCLE TRANSCRIPTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RNA SYNTHESIS MARKET SIZE, BY ROLLING CIRCLE TRANSCRIPTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RNA SYNTHESIS MARKET SIZE, BY ROLLING CIRCLE TRANSCRIPTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RNA SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RNA SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RNA SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RNA SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RNA SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RNA SYNTHESIS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RNA SYNTHESIS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RNA SYNTHESIS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RNA SYNTHESIS MARKET SIZE, BY POINT OF CARE DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RNA SYNTHESIS MARKET SIZE, BY POINT OF CARE DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RNA SYNTHESIS MARKET SIZE, BY POINT OF CARE DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RNA SYNTHESIS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RNA SYNTHESIS MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RNA SYNTHESIS MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RNA SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RNA SYNTHESIS MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL RNA SYNTHESIS MARKET SIZE, BY BASIC RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL RNA SYNTHESIS MARKET SIZE, BY BASIC RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RNA SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL RNA SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL RNA SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL RNA SYNTHESIS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL RNA SYNTHESIS MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL RNA SYNTHESIS MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL RNA SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL RNA SYNTHESIS MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RNA SYNTHESIS MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL RNA SYNTHESIS MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL RNA SYNTHESIS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL RNA SYNTHESIS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL RNA SYNTHESIS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL RNA SYNTHESIS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL RNA SYNTHESIS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL RNA SYNTHESIS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL RNA SYNTHESIS MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL RNA SYNTHESIS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL RNA SYNTHESIS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL RNA SYNTHESIS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL RNA SYNTHESIS MARKET SIZE, BY RAPID RESPONSE VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL RNA SYNTHESIS MARKET SIZE, BY RAPID RESPONSE VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL RNA SYNTHESIS MARKET SIZE, BY RAPID RESPONSE VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL RNA SYNTHESIS MARKET SIZE, BY SEASONAL VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL RNA SYNTHESIS MARKET SIZE, BY SEASONAL VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL RNA SYNTHESIS MARKET SIZE, BY SEASONAL VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL RNA SYNTHESIS MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL RNA SYNTHESIS MARKET SIZE, BY COMMERCIAL SCALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL RNA SYNTHESIS MARKET SIZE, BY COMMERCIAL SCALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL RNA SYNTHESIS MARKET SIZE, BY COMMERCIAL SCALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL RNA SYNTHESIS MARKET SIZE, BY COMMERCIAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL RNA SYNTHESIS MARKET SIZE, BY BULK MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL RNA SYNTHESIS MARKET SIZE, BY BULK MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL RNA SYNTHESIS MARKET SIZE, BY BULK MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL RNA SYNTHESIS MARKET SIZE, BY GMP PRODUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL RNA SYNTHESIS MARKET SIZE, BY GMP PRODUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL RNA SYNTHESIS MARKET SIZE, BY GMP PRODUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL RNA SYNTHESIS MARKET SIZE, BY LABORATORY SCALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL RNA SYNTHESIS MARKET SIZE, BY LABORATORY SCALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL RNA SYNTHESIS MARKET SIZE, BY LABORATORY SCALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL RNA SYNTHESIS MARKET SIZE, BY LABORATORY SCALE, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL RNA SYNTHESIS MARKET SIZE, BY PROTOTYPING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL RNA SYNTHESIS MARKET SIZE, BY PROTOTYPING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL RNA SYNTHESIS MARKET SIZE, BY PROTOTYPING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL RNA SYNTHESIS MARKET SIZE, BY RD USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL RNA SYNTHESIS MARKET SIZE, BY RD USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL RNA SYNTHESIS MARKET SIZE, BY RD USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL RNA SYNTHESIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL RNA SYNTHESIS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL RNA SYNTHESIS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL RNA SYNTHESIS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL RNA SYNTHESIS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL RNA SYNTHESIS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL RNA SYNTHESIS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL RNA SYNTHESIS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL RNA SYNTHESIS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL RNA SYNTHESIS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL RNA SYNTHESIS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL RNA SYNTHESIS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL RNA SYNTHESIS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL RNA SYNTHESIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS RNA SYNTHESIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS RNA SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS RNA SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS RNA SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS RNA SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS RNA SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS RNA SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS RNA SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS RNA SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS RNA SYNTHESIS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS RNA SYNTHESIS MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS RNA SYNTHESIS MARKET SIZE, BY COMMERCIAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS RNA SYNTHESIS MARKET SIZE, BY LABORATORY SCALE, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS RNA SYNTHESIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA RNA SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA RNA SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA RNA SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA RNA SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA RNA SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA RNA SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA RNA SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA RNA SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA RNA SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA RNA SYNTHESIS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA RNA SYNTHESIS MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA RNA SYNTHESIS MARKET SIZE, BY COMMERCIAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA RNA SYNTHESIS MARKET SIZE, BY LABORATORY SCALE, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA RNA SYNTHESIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA RNA SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA RNA SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA RNA SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA RNA SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA RNA SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA RNA SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA RNA SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA RNA SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA RNA SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA RNA SYNTHESIS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA RNA SYNTHESIS MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA RNA SYNTHESIS MARKET SIZE, BY COMMERCIAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA RNA SYNTHESIS MARKET SIZE, BY LABORATORY SCALE, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA RNA SYNTHESIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA RNA SYNTHESIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA RNA SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA RNA SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA RNA SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA RNA SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA RNA SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA RNA SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA RNA SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA RNA SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA RNA SYNTHESIS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA RNA SYNTHESIS MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA RNA SYNTHESIS MARKET SIZE, BY COMMERCIAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA RNA SYNTHESIS MARKET SIZE, BY LABORATORY SCALE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA RNA SYNTHESIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE RNA SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE RNA SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE RNA SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE RNA SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE RNA SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE RNA SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE RNA SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE RNA SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE RNA SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE RNA SYNTHESIS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE RNA SYNTHESIS MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE RNA SYNTHESIS MARKET SIZE, BY COMMERCIAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE RNA SYNTHESIS MARKET SIZE, BY LABORATORY SCALE, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE RNA SYNTHESIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST RNA SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST RNA SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST RNA SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST RNA SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST RNA SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST RNA SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST RNA SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST RNA SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST RNA SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST RNA SYNTHESIS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST RNA SYNTHESIS MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST RNA SYNTHESIS MARKET SIZE, BY COMMERCIAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST RNA SYNTHESIS MARKET SIZE, BY LABORATORY SCALE, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST RNA SYNTHESIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA RNA SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA RNA SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA RNA SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA RNA SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA RNA SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA RNA SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA RNA SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA RNA SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA RNA SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA RNA SYNTHESIS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA RNA SYNTHESIS MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA RNA SYNTHESIS MARKET SIZE, BY COMMERCIAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA RNA SYNTHESIS MARKET SIZE, BY LABORATORY SCALE, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA RNA SYNTHESIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC RNA SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC RNA SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC RNA SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC RNA SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC RNA SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC RNA SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC RNA SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC RNA SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC RNA SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC RNA SYNTHESIS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC RNA SYNTHESIS MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC RNA SYNTHESIS MARKET SIZE, BY COMMERCIAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC RNA SYNTHESIS MARKET SIZE, BY LABORATORY SCALE, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC RNA SYNTHESIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL RNA SYNTHESIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN RNA SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN RNA SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN RNA SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN RNA SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN RNA SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN RNA SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN RNA SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN RNA SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN RNA SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN RNA SYNTHESIS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN RNA SYNTHESIS MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN RNA SYNTHESIS MARKET SIZE, BY COMMERCIAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN RNA SYNTHESIS MARKET SIZE, BY LABORATORY SCALE, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN RNA SYNTHESIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. GCC RNA SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 246. GCC RNA SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. GCC RNA SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 248. GCC RNA SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 249. GCC RNA SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 250. GCC RNA SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 251. GCC RNA SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 252. GCC RNA SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 253. GCC RNA SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 254. GCC RNA SYNTHESIS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 255. GCC RNA SYNTHESIS MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 256. GCC RNA SYNTHESIS MARKET SIZE, BY COMMERCIAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 257. GCC RNA SYNTHESIS MARKET SIZE, BY LABORATORY SCALE, 2018-2032 (USD MILLION)
  • TABLE 258. GCC RNA SYNTHESIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION RNA SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION RNA SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION RNA SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION RNA SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION RNA SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION RNA SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION RNA SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION RNA SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION RNA SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION RNA SYNTHESIS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION RNA SYNTHESIS MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION RNA SYNTHESIS MARKET SIZE, BY COMMERCIAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION RNA SYNTHESIS MARKET SIZE, BY LABORATORY SCALE, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION RNA SYNTHESIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS RNA SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS RNA SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS RNA SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS RNA SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS RNA SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS RNA SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS RNA SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS RNA SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS RNA SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS RNA SYNTHESIS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS RNA SYNTHESIS MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS RNA SYNTHESIS MARKET SIZE, BY COMMERCIAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS RNA SYNTHESIS MARKET SIZE, BY LABORATORY SCALE, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS RNA SYNTHESIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. G7 RNA SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 288. G7 RNA SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. G7 RNA SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 290. G7 RNA SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 291. G7 RNA SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 292. G7 RNA SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 293. G7 RNA SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 294. G7 RNA SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 295. G7 RNA SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 296. G7 RNA SYNTHESIS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 297. G7 RNA SYNTHESIS MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 298. G7 RNA SYNTHESIS MARKET SIZE, BY COMMERCIAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 299. G7 RNA SYNTHESIS MARKET SIZE, BY LABORATORY SCALE, 2018-2032 (USD MILLION)
  • TABLE 300. G7 RNA SYNTHESIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 301. NATO RNA SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 302. NATO RNA SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. NATO RNA SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 304. NATO RNA SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 305. NATO RNA SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 306. NATO RNA SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 307. NATO RNA SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 308. NATO RNA SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 309. NATO RNA SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 310. NATO RNA SYNTHESIS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 311. NATO RNA SYNTHESIS MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 312. NATO RNA SYNTHESIS MARKET SIZE, BY COMMERCIAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 313. NATO RNA SYNTHESIS MARKET SIZE, BY LABORATORY SCALE, 2018-2032 (USD MILLION)
  • TABLE 314. NATO RNA SYNTHESIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 315. GLOBAL RNA SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES RNA SYNTHESIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED STATES RNA SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES RNA SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES RNA SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES RNA SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED STATES RNA SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES RNA SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED STATES RNA SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED STATES RNA SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED STATES RNA SYNTHESIS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED STATES RNA SYNTHESIS MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 327. UNITED STATES RNA SYNTHESIS MARKET SIZE, BY COMMERCIAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 328. UNITED STATES RNA SYNTHESIS MARKET SIZE, BY LABORATORY SCALE, 2018-2032 (USD MILLION)
  • TABLE 329. UNITED STATES RNA SYNTHESIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 330. CHINA RNA SYNTHESIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 331. CHINA RNA SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 332. CHINA RNA SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 333. CHINA RNA SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 334. CHINA RNA SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 335. CHINA RNA SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 336. CHINA RNA SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 337. CHINA RNA SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 338. CHINA RNA SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 339. CHINA RNA SYNTHESIS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 340. CHINA RNA SYNTHESIS MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 341. CHINA RNA SYNTHESIS MARKET SIZE, BY COMMERCIAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 342. CHINA RNA SYNTHESIS MARKET SIZE, BY LABORATORY SCALE, 2018-2032 (USD MILLION)
  • TABLE 343. CHINA RNA SYNTHESIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)